Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity

Journal of Immunology

Volumn 183, Issue 11, 2009, Pages 7326-7336

  Søndergaard, Henrik ^a,b   Coquet, Jonathan M ^b   Uldrich, Adam P ^a   McLaughlin, Nicole ^a   Godfrey, Dale I ^b   Sivakumar, Pallavur V ^d   Skak, Kresten ^c   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NOVO NORDISK A S   (Denmark)

^d ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; CYTOLOGY; EXPERIMENTAL NEOPLASM; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MOUSE MUTANT; NATURAL KILLER CELL; SIGNAL TRANSDUCTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOLOGIC MEMORY; IMMUNOLOGIC SURVEILLANCE; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-21; SIGNAL TRANSDUCTION;

EID: 73349115244     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902697     Document Type: Article

References (56)

1. Parrish-Novak, J., S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross, J. Johnston, K. Madden, W. Xu, J. West, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63.
2. Coquet, J. M., K. Kyparissoudis, D. G. Pellicci, G. Besra, S. P. Berzins, M. J. Smyth, and D. I. Godfrey. 2007. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178: 2827-2834. (Pubitemid 46333160)
3. Spolski, R., and W. J. Leonard. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26: 57-79. (Pubitemid 351600371)
4. Leonard, W. J., and R. Spolski. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5: 688-698. (Pubitemid 43086171)
5. Skak, K., M. Kragh, D. Hausman, M. J. Smyth, and P. V. Sivakumar. 2008. Interleukin 21: combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7: 231-240.
6. Wang, G., M. Tschoi, R. Spolski, Y. Lou, K. Ozaki, C. Feng, G. Kim, W. J. Leonard, and P. Hwu. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63: 9016-9022. (Pubitemid 38064083)
7. Takaki, R., Y. Hayakawa, A. Nelson, P. V. Sivakumar, S. Hughes, M. J. Smyth, and L. L. Lanier. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175: 2167-2173. (Pubitemid 41113822)
8. Smyth, M. J., M. E. Wallace, S. L. Nutt, H. Yagita, D. I. Godfrey, and Y. Hayakawa. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201: 1973-1985.
9. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173: 900-909.
10. + T cells and inhibits the growth of syngeneic tumors. Cancer Immunol. Immunother. 56: 1417-1428.
11. + T cell expansion and function. J. Exp. Med. 201: 139-148.
12. + regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J. Immunol. 176: 1750-1758.
13. Di Carlo, E., A. Comes, A. M. Orengo, O. Rosso, R. Meazza, P. Musiani, M. P. Colombo, and S. Ferrini. 2004. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172: 1540-1547. (Pubitemid 38116798)
14. Ma, H. L., M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, and K. Dunussi-Joannopoulos. 2003. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J. Immunol. 171: 608-615.
15. + memory T cell accumulation. Eur. J. Immunol. 37: 3069-3077.
16. Kasaian, M. T., M. J. Whitters, L. L. Carter, L. D. Lowe, J. M. Jussif, B. Deng, K. A. Johnson, J. S. Witek, M. Senices, R. F. Konz, et al. 2002. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16: 559-569.
17. Nakano, H., T. Kishida, H. Asada, M. Shin-Ya, T. Shinomiya, J. Imanishi, T. Shimada, S. Nakai, M. Takeuchi, Y. Hisa, and O. Mazda. 2006. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J. Gene Med. 8: 90-99.
18. Daga, A., A. M. Orengo, R. M. Gangemi, D. Marubbi, M. Perera, A. Comes, S. Ferrini, and G. Corte. 2007. Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int. J. Cancer 121: 1756-1763.
19. Maeda, M., Y. Yanagawa, K. Iwabuchi, K. Minami, Y. Nakamaru, D. Takagi, S. Fukuda, and K. Onoe. 2007. IL-21 enhances dendritic cell ability to induce interferon-γ production by natural killer T cells. Immunobiology 212: 537-547.
20. Davis, I. D., B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, and G. A. McArthur. 2007. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13: 3630-3636.
21. Davis, I. D., B. Brady, R. F. Kefford, M. Millward, J. Cebon, B. K. Skrumsager, U. Mouritzen, L. T. Hansen, K. Skak, D. Lundsgaard, et al. 2009. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin. Cancer Res. 15: 2123-2129.
22. + T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother. 57: 1439-1449.
23. Bubier, J. A., T. J. Sproule, O. Foreman, R. Spolski, D. J. Shaffer, H. C. Morse, III, W. J. Leonard, and D. C. Roopenian. 2009. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl. Acad. Sci. USA 106: 1518-1523.
24. +. J. Immunol. 182: 4649-4656.
25. Spolski, R., M. Kashyap, C. Robinson, Z. Yu, and W. J. Leonard. 2008. IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 105: 14028-14033.
26. Young, D. A., M. Hegen, H. L. Ma, M. J. Whitters, L. M. Albert, L. Lowe, M. Senices, P. W. Wu, B. Sibley, Y. Leathurby, T. P. Brown, C. Nickerson-Nutter, J. C. Keith, Jr., and M. Collins. 2007. Blockade of the interleukin-21/ interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56: 1152-1163.
27. Fina, D., M. Sarra, M. C. Fantini, A. Rizzo, R. Caruso, F. Caprioli, C. Stolfi, I. Cardolini, M. Dottori, M. Boirivant, F. Pallone, T. T. MacDonald, and G. Monteleone. 2008. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134: 1038-1048.
28. Gilfillan, S., C. J. Chan, M. Cella, N. M. Haynes, A. S. Rapaport, K. S. Boles, D. M. Andrews, M. J. Smyth, and M. Colonna. 2008. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205: 2965-2973.
29. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99: 1259-1266.
30. Swann, J. B., M. D. Vesely, A. Silva, J. Sharkey, S. Akira, R. D. Schreiber, and M. J. Smyth. 2008. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. USA 105: 652-656.
31. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196: 119-127.
32. Swann, J. B., and M. J. Smyth. 2007. Immune surveillance of tumors. J. Clin. Invest. 117: 1137-1146.
33. Brady, J., Y. Hayakawa, M. J. Smyth, and S. L. Nutt. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172: 2048-2058.
34. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
35. Hayakawa, Y., J. M. Kelly, J. A. Westwood, P. K. Darcy, A. Diefenbach, D. Raulet, and M. J. Smyth. 2002. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J. Immunol. 169: 5377-5381.
36. Carnaud, C., D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
37. Shimizu, K., A. Goto, M. Fukui, M. Taniguchi, and S. Fujii. 2007. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J. Immunol. 178: 2853-2861.
38. Nishimura, T., H. Kitamura, K. Iwakabe, T. Yahata, A. Ohta, M. Sato, K. Takeda, K. Okumura, K. L. Van, T. Kawano, et al. 2000. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 12: 987-994.
39. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171: 5140-5147.
40. + T cells in vivo. J. Immunol. 170: 2540-2548.
41. Coquet, J. M., S. Chakravarti, M. J. Smyth, and D. I. Godfrey. 2008. Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis. J. Immunol. 180: 7097-7101.
42. Nurieva, R., X. O. Yang, G. Martinez, Y. Zhang, A. D. Panopoulos, L. Ma, K. Schluns, Q. Tian, S. S. Watowich, A. M. Jetten, and C. Dong. 2007. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448: 480-483.
43. Street, S. E., E. Cretney, and M. J. Smyth. 2001. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood 97: 192-197.
44. Smyth, M. J., N. Y. Crowe, and D. I. Godfrey. 2001. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13: 459-463.
45. Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, K. L. Van, I. Saiki, and K. Okumura. 2001. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. 31: 1720-1727.
46. Casey, K. A., and M. F. Mescher. 2007. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J. Immunol. 178: 7640-7648.
47. Skak, K., K. S. Frederiksen, and D. Lundsgaard. 2008. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 123: 575-583.
48. Liu, S., G. Lizee, Y. Lou, C. Liu, W. W. Overwijk, G. Wang, and P. Hwu. 2007. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int. Immunol. 19: 1213-1221.
49. Brandt, K., S. Bulfone-Paus, A. Jenckel, D. C. Foster, R. Paus, and R. Ruckert. 2003. Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo. J. Invest. Dermatol. 121: 1379-1382.
50. Brandt, K., S. Bulfone-Paus, D. C. Foster, and R. Ruckert. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102: 4090-4098.
51. Yi, J. S., M. Du, and A. J. Zajac. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324: 1572-1576.
52. Elsaesser, H., K. Sauer, and D. G. Brooks. 2009. IL-21 is required to control chronic viral infection. Science 324: 1569-1572.
53. Frohlich, A., J. Kisielow, I. Schmitz, S. Freigang, A. T. Shamshiev, J. Weber, B. J. Marsland, A. Oxenius, and M. Kopf. 2009. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324: 1576-1580.
54. + T cell response. Mol. Immunol. 46: 1494-1504.
55. Spolski, R., H. P. Kim, W. Zhu, D. E. Levy, and W. J. Leonard. 2009. IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 182: 2859-2867.
56. Gelebart, P., Z. Zak, M. Anand, J. en-Bard, H. M. Amin, and R. Lai. 2009. Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism. Leukemia 23: 1836-1846.